The stock of Aurinia Pharmaceuticals Inc (TSE:AUP) is a huge mover today! About 23,100 shares traded hands. Aurinia Pharmaceuticals Inc (TSE:AUP) has risen 0.74% since March 28, 2016 and is uptrending. It has underperformed by 2.27% the S&P500.
The move comes after 8 months negative chart setup for the $145.25M company. It was reported on Nov, 1 by Barchart.com. We have $3.46 PT which if reached, will make TSE:AUP worth $18.88 million less.
Another recent and important Aurinia Pharmaceuticals Inc (TSE:AUP) news was published by Businesswire.com which published an article titled: “Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San …” on October 11, 2016.
Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has a market cap of $145.25 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.